BIOCON News Today

Biocon Ltd Share Price

BIOCON

CMP as on 16-Apr-24 12:00
₹ 264

icon -1.50 | -0.57%

Open
₹ 265
Turnover(lac)
₹ 9,190
Prev. Close
₹ 265.25
Day's Vol (shares)
₹ 3,484,465
Day's Vol (shares)
₹ 262.25         ₹ 269.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Biocon's Liraglutide Approval Spurs Stock Rise, Eyes UK Market Expansion

The application for Liraglutide was filed by Biocon through its European partner, Zentiva.

  • 28 Mar, 2024 |
  • 3:02 PM
Image not found

Biocon Biologics slips ~6% after CFO Indranil Sen steps down

Indranil Sen has resigned to seek possibilities outside of the organisation.

  • 15 Mar, 2024 |
  • 2:28 PM
Image not found

Eris Lifesciences purchases Biocon Biologics’ domestic brand formulations biz

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

  • 15 Mar, 2024 |
  • 11:38 AM
Image not found

Biocon soars on US market entry deal with J&J

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

  • 01 Mar, 2024 |
  • 11:31 AM
Image not found

Biocon Faces ₹3 Crore Penalty Over GST-Related Issues, Plans Appeal

The penalty of ₹3,03,78,465 was imposed on February 22, 2024, by the Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalor

  • 26 Feb, 2024 |
  • 4:20 PM
Image not found

Biocon: FY25 to be another washout year

Recommendation: Reduce; Target price: ₹225

  • 12 Feb, 2024 |
  • 12:41 PM
Image not found

Biocon Soars with ₹660 Crore Net Profit in Q3, Driven by Strong Revenue Growth

The company's revenue from operations surged by 34.4% to ₹3,953.7 Crore compared to the previous year.

  • 09 Feb, 2024 |
  • 3:00 PM
Image not found

Biocon's Q3 Sees Robust Growth: Net Profit Soars to ₹660 Crore

The company's revenue from operations experienced robust growth, increasing by 34.4% to ₹3,953.7 Crore compared to the previous year

  • 09 Feb, 2024 |
  • 12:12 PM
Image not found

Biocon's cancer drug gets USFDA nod, but investors remain cautious

Biocon was trading on the BSE at ₹295.15 at 9:29 a.m., down ₹3.60, or 1.21 %.

  • 07 Feb, 2024 |
  • 11:16 AM
Image not found

Biocon considers selling its $1.5 billion generic API company

"Discussions with investment banks have taken place but the plan (for sale of generic API business) is still on the drawing board," according to the report.

  • 15 Dec, 2023 |
  • 2:37 PM